AstraZeneca Announces First Regulatory Approval for New HFA pMDI ... 09 Feb 2006
...in the first European market, of a new pressurised metered-dose inhaler (pMDI) formulation of the inhaled corticosteroid Pulmicort® (budesonide) for the ... - PharmaLive.com (press release),
Orion Oyj: Orion group 2005 financial statements 09 Feb 2006
Ranbaxy in England. Budesonide and formoterol are being launched to the market as new choices in the Easyhaler franchise. Orion Pharma ... - Kauppalehti (press release),
TOPIGEN's CEO to Present at BIO CEO & Investor Conference 09 Feb 2006
...on the two programs. TPI-1020 is a novel, proprietary nitric-oxide donating derivative of budesonide. TOPIGEN screened, evaluated ... - Market Wire (press release)
MAP Pharmaceuticals Closes $25.25 Million Series C Financing Jan 25, 2006
MAP Pharmaceuticals is presently advancing a wholly-owned product portfolio of late-stage clinical compounds which includes: -- Unit dose budesonide (UDB): a ... - PR Newswire (press release),
MAP Pharmaceuticals closes $25.25 million series C financing Jan 26, 2006
Unit dose budesonide (UDB): a novel nanocrystalline form of budesonide which has demonstrated the potential to offer pediatric and adult asthma patients ... - American Venture Magazine (press release),
It is proved beyond doubt that asthma is affected beneficially by ... Jan 25, 2006
...hypothesis low dose synacthen test was performed in 72 asthmatic children on long-term treatment (6-84 months) with low to moderate doses of inhaled budesonide ... - MedIndia,
Breaking News ** Profits surge at AstraZeneca in Q4 Feb 2, 2006
...lipid-lowerer Crestor (rosuvastatin), Arimidex (anastrozole) for breast cancer and combination asthma treatment Symbicort (budesonide and formoterol). ... - Pharma Times (subscription),
DATAMONITOR: Get SMART: Symbicort gives patients the power to ... Jan 11, 2006
LONDON, January 11 2006- AstraZeneca is developing a new indication for its current leading asthma medication Symbicort (budesonide/formoterol), known as ... - PharmaLive.com (press release),
MAP Pharmaceuticals Closes $25.25 Million Series C Financing Jan 25, 2006
MAP's lead product candidate is a proprietary formulation of budesonide for the treatment of asthma in both pediatric and adult populations. ... - PharmaLive.com (press release),
Verus Pharmaceuticals Appoints Tutuncu as Vice President, Medical ... Jan 25, 2006
As Medical Director for pulmonary products, he developed and implemented clinical plans for late-stage products including budesonide, formoterol and Flutiform ... - PharmaLive.com (press release),
SkyePharma will not merge with Innovata Jan 12, 2006
...competing with blockbuster brands such as GlaxoSmithKline's Advair/Seretide (salmeterol and fluticasone) and AstraZeneca's Symbicort (formoterol and budesonide ... - Pharma Times (subscription),
AstraZeneca's Symbicort gives asthma patients the power to get ... Jan 13, 2006
AstraZeneca is focusing on Symbicort's (budesonide/formoterol) adaptability for adjustable dosing though SMART, which was formerly known as 'Single inhaler ... - Pharmaceutical Business Review
Connetics Acquires PediaMed Sales Organization; Enters Pediatric ... Jan 10, 2006
Genetic Engineering News, Desilux(TM) (desonide) VersaFoam-EF, 0.05%, a low-potency topical steroid formulated to treat atopic dermatitis, is Connetics' first drug candidate seeking a ...
Connetics Names David Burch, Regional Sales Director, Ohio and ... Jan 9, 2006
Genetic Engineering News, Foam, 1%. Connetics is developing Velac(R) (a combination of 1% clindamycin and 0.025% tretinoin) Gel, for treating acne; Desilux(TM) (desonide) VersaFoam-EF ...
PGA TOUR: Campbell, Toms win for charity Jan 15, 2006
noticias.info, ...of products that make significant contributions to treatment options and patient care including CRESTOR, NEXIUM, SEROQUEL, ARIMIDEX, and PULMICORT RESPULES. ...
ROUNDUP SkyePharma future remains clouded Jan 11, 2006
Forbes It has worked on top selling drugs such as GlaxoSmithKline PLC's Paxil CR, Novartis AG's Foradil and AstraZeneca PLC's Pulmicort. ...
SIXTH ANNUAL REPORT: FUTURE BLOCKBUSTERS Dec 30, 2005
Med Ad News (subscription), Budesonide is the main chemical in AstraZeneca’s (astrazeneca.com) billion-dollar respiratory drug Pulmicort. Besides Flovent ...
S&P Ups Marsh & Mclennan, Cuts Astrazeneca Dec 20, 2005
BusinessWeek Astrazeneca's present valuation will be difficult to sustain in light of increased generic threats to key drugs such as Nexium, Seroquel and Pulmicort, as well ...
AstraZeneca "underperform" Dec 20, 2005
New Ratings ...note published this morning, the analysts mention that the company has witnessed three patent challenges in the US in 3Q05 for Seroquel, Nexium and Pulmicort. ...
Health News Dec 20, 2005
Hampton Union, ...qualify. If you take Flovent, Combivent, Proventil, Advair, Pulmicort, Serevent, Atrovent or any other inhaler, the program may help. ...
PGA TOUR: Campbell, Toms win for charity Jan 15, 2006
noticias.info, ...of products that make significant contributions to treatment options and patient care including CRESTOR, NEXIUM, SEROQUEL, ARIMIDEX, and PULMICORT RESPULES. ...
Treating inflamed nasal area is routine Dec 18, 2005
Daytona Beach News-Journal, ...available to control sneezing, itching, a runny nose and nasal congestion are corticosteroid nasal sprays such as Flonase, Nasacort AQ, Nasonex and Rhinocort AQ ...
